Marshall Wace
ALGS icon

Marshall Wace’s Aligos Therapeutics ALGS Stock Holding History

Marshall Wace’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.98M Sell
267,135
-1,529
-0.6% -$11.6K ﹤0.01% 1792
2025
Q4 		$2.5M Buy
+268,664
New +$2.53M ﹤0.01% 1469
2023
Q2 		– Sell
-4,344
Closed -$94.5K – 2417
2023
Q1 		$94.5K Buy
+4,344
New +$166K ﹤0.01% 2503

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.2B AUM 41.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Marshall Wace's ALGS Position: Q1 2026 in Review

Marshall Wace reduced its Aligos Therapeutics (ALGS) stake by 0.57% in Q1 2026, selling an estimated $11.6K and leaving 267,135 shares worth $1.98M. The position accounts for ﹤0.01% of the portfolio, ranked #1792.

Marshall Wace first reported a position in ALGS in Q1 2023 and has held it in 3 quarters since. The position peaked at $2.5M in Q4 2025. 35 funds tracked by Wall St. Rank hold ALGS as of Q1 2026.

  • Marshall Wace held 267,135 shares of Aligos Therapeutics worth $1.98M as of Q1 2026.
  • Marshall Wace sold 1,529 Aligos Therapeutics shares in Q1 2026, an estimated $11.6K.
  • Aligos Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #1792 holding.
  • Marshall Wace first reported a position in Aligos Therapeutics in Q1 2023 and has held it in 3 quarters since.
  • Marshall Wace's Aligos Therapeutics position peaked at $2.5M in Q4 2025.
  • 35 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.